Edwards Lifesciences Q2 net sales rose 13.6% to $1.74 billion; GAAP diluted EPS fell to $0.42.
GAAP net income attributable to shareholders dropped to $241.9 million; the effective tax rate widened to 53.6%.
TMTT net sales more than doubled to $195.9 million; TAVR net sales climbed 11.3% to $1.26 billion.
2026 outlook and management commentary
The company raised its 2026 outlook for total company net sales growth to 10%–11%; adjusted EPS guidance was held at $2.95–$3.05.
CEO Bernard Zovighian cited stronger-than-expected sales growth, supported by contributions across regions and therapies including TAVR, mitral, tricuspid and surgical.
EW•
